RxDoctor Payments Data

Ashley Huggins

Family · Georgiana, ALNPI 1225556350

Payments from drug & device makers

$1,760in general payments, 2019–2025

Across 102 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$563
  • Novo Nordisk$439
  • AbbVie$212
  • AstraZeneca$113
  • Mannkind Corporation$76
  • Lilly USA, LLC$69
  • plus $288 from 12 others

What the payments were for

  • Food & beverage$1,68196%
  • Education$191%
  • Gifts$593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,760 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$3,610
Medicare patients
31
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$102,246
OzempicSemaglutide89$98,800
FarxigaDapagliflozin Propanediol85$58,799
Tresiba Flextouch U-100Insulin Degludec53$36,154
RybelsusSemaglutide19$26,332
EliquisApixaban32$25,924
LinzessLinaclotide22$22,214
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$17,733
JardianceEmpagliflozin16$15,062
KerendiaFinerenone22$14,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,912
TrulicityDulaglutide11$10,989
Tresiba Flextouch U-200Insulin Degludec20$10,780
Repatha SureclickEvolocumab16$8,626
SymbicortBudesonide/Formoterol Fumarate28$7,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$439$125,132108 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$69$114,89787 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$113$83,640128 claims
AbbVieLinzess$212$22,21422 claims
Boehringer IngelheimJardiance$19$15,06216 claims
BayerKerendia$563$14,42722 claims
GSKTrelegy Ellipta$16$12,91211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Georgiana

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →